Cystic fibrosis treatment targets the disease from multiple angles: thinning and clearing mucus from the lungs, fighting infections, helping the body absorb nutrients, and, for most patients, correcting the underlying protein defect that causes the disease. Treatment is daily and lifelong, but advances over the past decade have dramatically improved both life expectancy and quality of life for people with CF.
CFTR Modulators: Treating the Root Cause
The biggest breakthrough in CF treatment has been a class of drugs called CFTR modulators. In CF, a faulty gene produces a defective protein that can’t properly regulate the flow of salt and water in and out of cells. This is what causes the thick, sticky mucus that clogs the lungs and digestive system. CFTR modulators fix the defective protein so it works more like it should.
These drugs use two strategies in combination. “Correctors” help the misshapen protein fold into the right shape and travel to the cell surface. “Potentiators” then hold open the protein’s chloride channel, like propping open a gate, so salt and water can flow through normally. Most current modulators combine both types in a single regimen.
Trikafta, approved for people ages 2 and older with at least one copy of the F508del mutation (the most common CF mutation) or one of 271 other mutations, combines two correctors with a potentiator. It was a landmark drug because it made modulator therapy available to roughly 90% of the CF population. A newer option, Alyftrek, uses a modified potentiator that allows once-daily dosing instead of twice daily, and is approved for ages 6 and older. Older modulators like Symdeko and Orkambi remain options for specific mutation profiles, while Kalydeco works as a potentiator alone for people with certain gating mutations.
For the estimated 10% of people with CF whose mutations don’t respond to any current modulator, symptom management remains the primary approach while new therapies, including mRNA-based treatments that could work regardless of mutation type, are in development.
Airway Clearance
Even with modulator therapy, daily airway clearance is a cornerstone of CF care. The goal is to loosen and move mucus out of the lungs before it can trap bacteria and cause infection. These techniques are typically performed at least twice a day.
One of the most common methods uses a high-frequency chest wall oscillation vest. You wear an inflatable vest connected to a machine that vibrates rapidly, shaking mucus loose from the airway walls. You pause periodically to cough the mucus out. For people who prefer something more portable, positive expiratory pressure (PEP) devices create resistance when you breathe out through a mask or handheld mouthpiece. This pushes air behind the mucus to break it up and move it toward the larger airways where it can be coughed out.
Breathing techniques like the active cycle of breathing combine phases of relaxed breathing, deep breathing to get air behind mucus, and forced exhalation (huffing) to push it out. Many people with CF use a combination of these approaches depending on their age, lifestyle, and how they’re feeling on a given day.
Inhaled Medications to Thin Mucus
Before airway clearance sessions, most people with CF inhale medications that make their mucus thinner and easier to move. Dornase alfa is an inhaled enzyme that breaks down DNA released by dead white blood cells in the lungs. This DNA is a major reason CF mucus becomes so thick and glue-like.
Inhaled hypertonic saline, a concentrated saltwater solution typically at 6% or 7% concentration, draws water into the airways through osmosis, hydrating the mucus and making it less sticky. Studies have tested concentrations up to 12%, but solutions that strong tend to irritate the upper airway, which is why 7% has become the standard in most clinical practice. A bronchodilator is usually inhaled first to prevent the saline from triggering airway tightening.
Fighting Lung Infections
The thick mucus in CF lungs creates an ideal environment for bacterial infections, and one organism in particular, Pseudomonas aeruginosa, is a persistent threat. When Pseudomonas is first detected, aggressive treatment aims to eradicate it before it establishes a chronic infection. A standard eradication course is 28 days of inhaled tobramycin, which clinical trials have shown to be as effective as longer 56-day courses.
For people with chronic Pseudomonas infections that can’t be fully cleared, inhaled antibiotics are often used in alternating 28-day on/off cycles to suppress bacterial growth and slow lung damage. Inhaled aztreonam is another option studied for Pseudomonas eradication. During acute flare-ups, called pulmonary exacerbations, intravenous antibiotics and intensified airway clearance are typically needed, sometimes requiring a hospital stay of one to two weeks.
Digestive Support and Nutrition
About 85% of people with CF have pancreatic insufficiency, meaning the thick mucus blocks digestive enzymes from reaching the small intestine. Without these enzymes, the body can’t properly break down fats, proteins, and certain vitamins from food. The result is poor weight gain, nutrient deficiencies, and greasy, bulky stools.
Pancreatic enzyme replacement capsules are taken with every meal and snack to do the work the pancreas can’t. Dosing is individualized based on body weight and the fat content of the meal. For older children and adults, the typical range is 500 to 2,500 lipase units per kilogram of body weight per meal, with half that amount for snacks, across three meals and two to three snacks daily. Doses above 2,500 units per kilogram per meal require closer monitoring due to the risk of intestinal complications.
People with CF also typically need fat-soluble vitamin supplements (A, D, E, and K) and a high-calorie diet. Because of increased energy demands from breathing harder and fighting infections, caloric needs can be 20% to 50% higher than for someone without CF.
Exercise as Treatment
Regular physical activity is considered part of the treatment plan, not just a lifestyle recommendation. Aerobic exercise improves lung function, exercise capacity, and quality of life. It also serves as a natural form of airway clearance, since vigorous movement and deeper breathing help mobilize mucus. Studies have found that people with CF who improve their exercise capacity show measurable increases in lung function and tend to be more physically active in daily life, creating a positive cycle.
When Lung Transplant Becomes an Option
For people whose lung function continues to decline despite optimal treatment, lung transplantation may become necessary. The Cystic Fibrosis Foundation recommends that care teams begin discussing transplantation when lung function drops below 50% of predicted values (measured by a breathing test called FEV1). A formal transplant referral is recommended when FEV1 falls below 40% and the person has had a collapsed lung.
Regardless of lung function numbers, transplant evaluation is recommended when other warning signs appear: being unable to walk 400 meters in six minutes, low oxygen levels at rest or during activity, elevated carbon dioxide levels, or high blood pressure in the lung arteries. Women with CF and people with shorter stature (under 162 cm) may be referred earlier, since these groups tend to experience faster disease progression or face longer wait times for donor organs of the right size.
Transplantation is not a cure for CF. The new lungs won’t develop CF, but the disease still affects the sinuses, pancreas, and other organs, so most other CF treatments continue after transplant. Anti-rejection medications are added for life.